RENVELA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $25,664 | 8 | 1 |
| 2018 | $266.62 | 14 | 14 |
| 2017 | $132,149 | 2,266 | 1,246 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,829 | 10 | 50.5% |
| Food and Beverage | $40,183 | 2,244 | 25.4% |
| Travel and Lodging | $27,238 | 24 | 17.2% |
| Unspecified | $5,498 | 7 | 3.5% |
| Consulting Fee | $5,332 | 3 | 3.4% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease | GENZYME CORPORATION | $5,498 | 7 |
Top Doctors Receiving Payments for RENVELA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Nephrology | Rochester, NY | $68,003 | 22 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $13,341 | 4 |
| , M.D | Internal Medicine | Houston, TX | $10,813 | 4 |
| , MD | Internal Medicine | Chicago, IL | $8,794 | 7 |
| Unknown | — | San Francisco, CA | $7,000 | 3 |
| , MD | Family Medicine | Santa Ana, CA | $2,272 | 1 |
| , MD | Internal Medicine | Boston, MA | $1,880 | 1 |
| , M.D | Internal Medicine | Houston, TX | $1,207 | 2 |
| , M.D | Pediatric Nephrology | Los Angeles, CA | $785.41 | 1 |
| Hassan Fathallah Sha | Neurology | Birmingham, AL | $785.41 | 1 |
| , MD MPH | Pediatric Nephrology | Albuquerque, NM | $785.41 | 1 |
| , MD | Pediatrics | Houston, TX | $785.41 | 1 |
| , MD | Pediatric Nephrology | Boise, ID | $785.41 | 1 |
| , MD | Pediatric Nephrology | Seattle, WA | $785.41 | 1 |
| , MD | Pediatric Nephrology | Kansas City, MO | $785.41 | 1 |
| , M.D | Nephrology | Cincinnati, OH | $182.39 | 13 |
| , MD | Nephrology | Westerville, OH | $172.83 | 11 |
| , MD | Nephrology | Somerset, NJ | $160.20 | 8 |
| , MD | Nephrology | Brick, NJ | $156.71 | 7 |
| , M.D | Nephrology | Brick, NJ | $153.32 | 7 |
| , MD | Nephrology | Somerset, NJ | $152.59 | 8 |
| , MD | Nephrology | South River, NJ | $146.86 | 7 |
| , MD | Nephrology | Coral Gables, FL | $138.17 | 7 |
| , M.D | Internal Medicine | Columbus, OH | $136.68 | 9 |
| , M.D | Nephrology | Orange, CA | $124.70 | 6 |
Manufacturing Companies
- SANOFI-AVENTIS U.S. LLC $131,370
- GENZYME CORPORATION $26,710
Product Information
- Type Drug
- Total Payments $158,080
- Total Doctors 1,251
- Transactions 2,288
About RENVELA
RENVELA is a drug associated with $158,080 in payments to 1,251 healthcare providers, recorded across 2,288 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.
Payment data is available from 2017 to 2019. In 2019, $25,664 was paid across 8 transactions to 1 doctors.
The most common payment nature for RENVELA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,829, 50.5% of total).
RENVELA is associated with 1 research study, including "Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease" ($5,498).